絞り込み

16633

広告

Making urothelial carcinomas less immune to immunotherapy.

著者 Ramos JD , Yu EY
Urol Oncol.2016 12 ; 34(12):534-537.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Medical

The success of immune checkpoint inhibitors in advanced urothelial carcinoma provides patients with the prospect for durable objective responses. However, the majority of patients do not respond to immune checkpoint blockade. Several potential predictive biomarkers of response have been evaluated in hopes of better identifying likely responders, though each has been shown to have limitations. Going forward, development of reliable predictive biomarkers is imperative. Likewise, innovative treatment combination approaches to convert non-responders to responders are essential to continue making progress in the field.
PMID: 27836245 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード